Amarin Corporation PLC(AMRN)stock report

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.

Finance:
Market Cap:7100M; Shares Outstanding:358.9M; Short Interest: 12.81%; Q3 2019(9/30/19): Cash 673M. Loss 3.46M

EPS and Sales:
https://finance.yahoo.com/quote/AMRN/financials?p=AMRN

Date EPS % last year % last quarter
2018.12.31 -0.39 -56.00% 39.29%
2019.3.31 -0.07 12.50% 82.05%
2019.6.31 -0.08 60.00% 6.00%
2019.9.30 -0.09 67.86% -12.50%

 

Date Sales % last year % last quarter
2018.12.31 229M 26.56% 33.62%
2019.3.31 73.28M 66.85% -68.00%
2019.6.31 174M 80.27% 137.45%
2019.9.30 286M 88.62% 64.37%

 

Insider Transactions:
http://insidercow.com/history/company.jsp?company=AMRN&B1=Search%21

Institution Ownership:
https://www.marketbeat.com/stocks/NYSE/AMRN/institutional-ownership/

2019.12.09:
Total institutions: 320,no change
Shares hold: 197000k shares. no change
shares% hold: 54.87%,no change

Analyst Ratings:
https://www.tipranks.com/stocks/AMRN/price-targe

NEWS:

2020.01.28: Could Amarin Be a Millionaire Maker Stock?

2020.01.04:3 Top Biotech Stocks to Buy in January

2019-12-16: Citing valuation and litigation risks, Stifel’s Derek Archila has downgraded Amarin to Hold with a $28 price target.

2019-12-09: AMRN: Market Headwinds and Inherent Weakness of the Vascepa IP

Leave a Reply